Forte Biosciences, Inc. (FBRX)
76.99
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
Forte Biosciences Research and Development Expense (Quarterly) : 22.34M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 22.34M |
| March 31, 2026 | 20.47M |
| December 31, 2025 | 21.74M |
| September 30, 2025 | 15.20M |
| June 30, 2025 | 8.619M |
| March 31, 2025 | 12.69M |
| December 31, 2024 | 5.23M |
| September 30, 2024 | 5.87M |
| June 30, 2024 | 5.74M |
| March 31, 2024 | 4.353M |
| December 31, 2023 | 3.567M |
| September 30, 2023 | 6.369M |
| June 30, 2023 | 7.139M |
| March 31, 2023 | 4.787M |
| December 31, 2022 | 2.488M |
| September 30, 2022 | 1.379M |
| June 30, 2022 | 1.034M |
| March 31, 2022 | 0.693M |
| December 31, 2021 | 1.352M |
| September 30, 2021 | 5.647M |
| Date | Value |
|---|---|
| June 30, 2021 | 3.51M |
| March 31, 2021 | 3.308M |
| December 31, 2020 | 3.011M |
| September 30, 2020 | 3.675M |
| June 30, 2020 | 1.937M |
| March 31, 2020 | 1.341M |
| December 31, 2019 | 1.158M |
| September 30, 2019 | 0.353M |
| June 30, 2019 | 0.31M |
| March 31, 2019 | 12.22M |
| December 31, 2018 | 15.42M |
| September 30, 2018 | 12.06M |
| June 30, 2018 | 12.64M |
| March 31, 2018 | 10.44M |
| December 31, 2017 | 8.294M |
| September 30, 2017 | 7.563M |
| June 30, 2017 | 6.632M |
| March 31, 2017 | 6.624M |
| June 30, 2016 | 6.53M |
| March 31, 2016 | 6.469M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| argenx SE | -- |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |
| Savara, Inc. | 21.95M |